Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected investment return that will outperform the market benchmark by over 20% in the next 6-12 months [5][11]. Core Insights - The company achieved a revenue of 4.47 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 1.2%, while the net profit attributable to the parent company reached 670 million yuan, up 15.8% [1][5]. - The gross margin improved to 26.9%, an increase of 0.7 percentage points, and the net margin rose to 14.9%, up 1.8 percentage points [1][5]. - The decline in revenue for Q3 was primarily due to weak demand for antibiotics and the traditional off-season for raw materials, but profitability continued to improve with rising margins [1][2]. - The company has a diverse product matrix with over 70 chemical drug products, 13 of which generate over 100 million yuan in revenue, and nearly 20 products hold leading market shares [2]. Financial Projections - Revenue forecasts for 2025-2027 are 6.41 billion yuan, 7.29 billion yuan, and 8.17 billion yuan, reflecting year-on-year growth rates of 8.8%, 13.6%, and 12.2% respectively [3][10]. - The net profit projections for the same period are 943 million yuan, 1.16 billion yuan, and 1.38 billion yuan, with growth rates of 20.6%, 23.2%, and 18.5% respectively [3][10]. - The report highlights a continuous improvement in profitability driven by the company's market share in animal health products and cost efficiencies [3][10].